OncoMatch/Clinical Trials/NCT07447050

Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial

Is NCT07447050 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Riluzole for breast cancer.

Phase 2RecruitingUniversity of California, IrvineNCT07447050Data as of May 2026

Treatment: Riluzole — This is a phase II single-arm, Phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining efficacy of riluzole in preventing cognitive dysfunction in subjects with cancer, who are receiving chemotherapy.

Check if I qualify

Extracted eligibility criteria

Cancer type

Breast Carcinoma

Sarcoma

Non-Small Cell Lung Carcinoma

Head and Neck Squamous Cell Carcinoma

Colorectal Cancer

Ovarian Cancer

Hepatocellular Carcinoma

Lab requirements

Liver function

ast and/or alt < 3 x upper limit normal (uln)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Chao Family Comprehensive Cancer Center, University of California Irvine · Orange, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify